New ADHD medications: what is genuinely new, and what is repackaging.

Genuinely new medications

Viloxazine (Qelbree)

The most significant recent addition. Viloxazine is a non-stimulant, FDA-approved for children in 2021 and for adults in 2022 — the first new non-stimulant mechanism for ADHD in roughly two decades.

It is a norepinephrine reuptake inhibitor with additional serotonergic activity, which distinguishes it from atomoxetine. Practical notes: adult dosing is 200–600 mg once daily, onset is faster than atomoxetine (some benefit in the first one to two weeks rather than four to six), and it is not a controlled substance. Side effects include somnolence, fatigue, nausea, and reduced appetite; it carries the same boxed warning for suicidal ideation as other ADHD non-stimulants. It is a meaningful CYP1A2 inhibitor, which matters if you take duloxetine, clozapine, or theophylline.

Serdexmethylphenidate / dexmethylphenidate (Azstarys)

Approved in 2021. It combines immediate-release dexmethylphenidate with serdexmethylphenidate, a prodrug that converts to active drug in the lower gastrointestinal tract. The result is rapid onset from the immediate-release component and an extended tail from the prodrug, in a single capsule.

The prodrug design has a secondary benefit: it is difficult to misuse by snorting or injecting, since conversion requires GI transit. Same mechanism as methylphenidate, though — the innovation is delivery, not pharmacology.

New delivery, familiar molecule

• Xelstrym (dextroamphetamine transdermal, 2022) — the first amphetamine patch. Genuinely useful for people who cannot swallow pills or have absorption issues, and the wear time can be shortened to end the effect early. Skin irritation is the main drawback.
• Onyda XR (clonidine extended-release oral suspension, 2024) — the first liquid non-stimulant for ADHD, dosed at night. Same clonidine that has been used for decades, in a formulation that helps people who cannot take tablets.
• Jornay PM — delayed-release methylphenidate taken in the evening, designed to be active on waking. Clever for people whose worst hour is the morning routine before a morning dose could possibly work.
• Chewable, liquid, and orally disintegrating formulations of methylphenidate and amphetamine — QuilliChew, Quillivant, Adzenys, Dyanavel. Real quality-of-life improvements for a subset of patients; no pharmacological novelty.

What is in development

Several approaches are in clinical trials, including centanafadine (a triple reuptake inhibitor), novel dopamine-modulating agents, and non-drug options such as trigeminal nerve stimulation, which already has a pediatric FDA clearance.

Worth being sober about timelines. Most compounds in trials never reach market, and those that do arrive years later at brand pricing. Treatment decisions should be made with what is available now.

Is newer better?

Usually not, and it is worth saying plainly. Methylphenidate and amphetamine remain the most effective ADHD treatments available, with effect sizes no newer agent has beaten. They have been in use for decades, which means their safety profile is understood in a way a 2024 approval's is not.

Newer medications are valuable for specific problems, not as a general upgrade:

• You cannot take a controlled substance — viloxazine expands the non-stimulant options beyond atomoxetine, guanfacine, and bupropion
• You cannot swallow pills — patches, liquids, and chewables solve a real problem
• You need a different release curve — morning coverage before a dose can act, or a shorter tail to protect sleep
• You have failed multiple standard options and need something with a different mechanism

If a standard generic works well, switching to something newer is usually a downgrade in cost and hassle with no clinical gain.

Cost and coverage

Every medication listed above is brand-only. Expect list prices in the $300–$500 per month range, and expect insurers to require prior authorization plus documented failure of one or two generics first.

Manufacturer copay cards can bring commercial-insurance costs down substantially but are not usable with Medicare or Medicaid. Generic alternatives run $4–$60 a month. That difference is worth weighing honestly — a medication you cannot afford to refill consistently is worse than a generic you can. More detail in what ADHD treatment costs.

Who should ask about a newer option

Bring it up if you have tried both stimulant classes without success, cannot tolerate stimulant side effects, need a non-controlled option, have trouble with tablets, or have a specific coverage-window problem that current formulations do not solve.

Bring the specifics to the appointment — which agents, which doses, what happened. A precise history is what determines whether a newer medication is a reasonable next step or an expensive detour. See also what to do when ADHD medication is not working.

Frequently asked questions